BIOGEN INC. DL -,0005BIOGEN INC. DL -,0005BIOGEN INC. DL -,0005

BIOGEN INC. DL -,0005

No trades
See on Supercharts
Next report date
Report period
EPS estimate
Revenue estimate
Market capitalization
‪22.82 B‬EUR
9.98EUR
‪1.05 B‬EUR
‪8.53 B‬EUR
‪144.59 M‬
Beta (1Y)
0.78
Employees (FY)
‪7.57 K‬
Change (1Y)
‪−1.16 K‬ −13.24%
Revenue / Employee (1Y)
‪1.24 M‬EUR
Net income / Employee (1Y)
‪153.38 K‬EUR

About Biogen Inc.


CEO
Christopher A. Viehbacher
Headquarters
Cambridge
Website
Founded
1978
FIGI
BBG000K21XJ8
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
US9062XAD5
BIOGEN INC. 15/45
Yield to maturity
5.92%
Maturity date
Sep 15, 2045
BIIB4981508
Biogen Inc. 3.15% 01-MAY-2050
Yield to maturity
5.49%
Maturity date
May 1, 2050
BIIB5133378
Biogen Inc. 3.25% 15-FEB-2051
Yield to maturity
5.43%
Maturity date
Feb 15, 2051
BIIB4981506
Biogen Inc. 2.25% 01-MAY-2030
Yield to maturity
5.11%
Maturity date
May 1, 2030
IDPC
BIOGEN INC. 15/25
Yield to maturity
4.83%
Maturity date
Sep 15, 2025
BIIB5133379
Biogen Inc. 3.25% 15-FEB-2051
Yield to maturity
4.28%
Maturity date
Feb 15, 2051

Explore more bonds 

Curated watchlists where IDP is featured.

Frequently Asked Questions


The current price of IDP is 152.30 EUR — it has decreased by −3.58% in the past 24 hours. Watch BIOGEN INC. DL -,0005 stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on DUS exchange BIOGEN INC. DL -,0005 stocks are traded under the ticker IDP.
IDP stock has fallen by −5.26% compared to the previous week, the month change is a −13.32% fall, over the last year BIOGEN INC. DL -,0005 has showed a −27.55% decrease.
We've gathered analysts' opinions on BIOGEN INC. DL -,0005 future price: according to them, IDP price has a max estimate of 324.80 EUR and a min estimate of 170.95 EUR. Watch IDP chart and read a more detailed BIOGEN INC. DL -,0005 stock forecast: see what analysts think of BIOGEN INC. DL -,0005 and suggest that you do with its stocks.
IDP reached its all-time high on Mar 23, 2015 with the price of 405.56 EUR, and its all-time low was 24.20 EUR and was reached on Mar 30, 2005. View more price dynamics on IDP chart.
See other stocks reaching their highest and lowest prices.
IDP stock is 3.94% volatile and has beta coefficient of 0.78. Track BIOGEN INC. DL -,0005 stock price on the chart and check out the list of the most volatile stocks — is BIOGEN INC. DL -,0005 there?
Today BIOGEN INC. DL -,0005 has the market capitalization of ‪22.14 B‬, it has decreased by −2.55% over the last week.
Yes, you can track BIOGEN INC. DL -,0005 financials in yearly and quarterly reports right on TradingView.
BIOGEN INC. DL -,0005 is going to release the next earnings report on Jan 30, 2025. Keep track of upcoming events with our Earnings Calendar.
IDP earnings for the last quarter are 3.66 EUR per share, whereas the estimation was 3.39 EUR resulting in a 8.15% surprise. The estimated earnings for the next quarter are 3.28 EUR per share. See more details about BIOGEN INC. DL -,0005 earnings.
BIOGEN INC. DL -,0005 revenue for the last quarter amounts to ‪2.21 B‬ EUR, despite the estimated figure of ‪2.19 B‬ EUR. In the next quarter, revenue is expected to reach ‪2.29 B‬ EUR.
IDP net income for the last quarter is ‪348.93 M‬ EUR, while the quarter before that showed ‪544.85 M‬ EUR of net income which accounts for −35.96% change. Track more BIOGEN INC. DL -,0005 financial stats to get the full picture.
No, IDP doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 16, 2024, the company has ‪7.57 K‬ employees. See our rating of the largest employees — is BIOGEN INC. DL -,0005 on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. BIOGEN INC. DL -,0005 EBITDA is ‪2.47 B‬ EUR, and current EBITDA margin is 22.58%. See more stats in BIOGEN INC. DL -,0005 financial statements.
Like other stocks, IDP shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade BIOGEN INC. DL -,0005 stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So BIOGEN INC. DL -,0005 technincal analysis shows the strong sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating BIOGEN INC. DL -,0005 stock shows the strong sell signal. See more of BIOGEN INC. DL -,0005 technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.